Comparative Pharmacology
Head-to-head clinical analysis: HEPARIN SODIUM 5 000 UNITS AND SODIUM CHLORIDE 0 9 IN PLASTIC CONTAINER versus MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEPARIN SODIUM 5 000 UNITS AND SODIUM CHLORIDE 0 9 IN PLASTIC CONTAINER versus MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER.
HEPARIN SODIUM 5,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Heparin binds to antithrombin III, causing a conformational change that accelerates the inactivation of factor Xa and thrombin, thereby inhibiting coagulation.
Magnesium sulfate provides magnesium ions, which are essential for various physiological processes. It acts as a cofactor for enzymatic reactions, stabilizes excitable membranes, and antagonizes calcium entry at the neuromuscular junction, leading to reduced acetylcholine release and muscle relaxation. In the CNS, it may act as a noncompetitive antagonist of NMDA receptors, exerting anticonvulsant effects.
For venous thromboembolism prophylaxis: 5000 units subcutaneously every 8-12 hours. For therapeutic anticoagulation: weight-based IV bolus (60-80 units/kg) followed by continuous IV infusion (12-18 units/kg/hour) adjusted to target aPTT. 1.5-2.5 times control.
1 to 4 g intravenously as a 5% to 20% solution, rate not exceeding 150 mg/min; dosing frequency depends on indication (e.g., preeclampsia/eclampsia: 4-5 g IV loading then 1-2 g/hr infusion; hypomagnesemia: 1-2 g IV over 1-2 hours, may repeat based on serum magnesium levels).
None Documented
None Documented
The terminal elimination half-life of heparin is dose-dependent, ranging from 0.5 to 2 hours for intravenous doses of 100-400 U/kg. At higher doses, half-life may extend to 2.5 hours. Clinical context: linear pharmacokinetics; half-life increases with dose due to saturable clearance mechanisms (reticuloendothelial uptake and hepatic metabolism).
Terminal half-life approximately 4-5 hours in normal renal function; prolonged in renal impairment (up to 40 hours).
Heparin is primarily eliminated via the reticuloendothelial system and metabolized in the liver. Renal excretion of unchanged heparin is minimal (<5%) at therapeutic doses. Biliary/fecal excretion is negligible.
Primarily renal (90-100% as unchanged magnesium). Less than 1% biliary/fecal.
Category A/B
Category C
Electrolyte
Electrolyte